Bharat Parenterals Limited (BPLPHARMA) fundamentals
Bharat Parenterals Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as BPLPHARMA (ISIN INE365Y01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Bharat Parenterals Limited does
Bharat Parenterals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of pharmaceutical formulations. The Company offers a range of products, including B-lactam antibiotics, anti-retroviral, cephalosporins antibiotics, antiprotozoal / anthelmintic, respiratory, antiallergic / anti histaminic / anticold, cleansing agents/skin infections, antibiotic, cardiovascular system, anti-diabetic, anti-tuberculosis, anti-fungal, antimalarial, gastroinestinaltract / alimentary system, anti-inflammatory / anti pyretic / analgesic, supplements, central nervous system, anesthetics, anti-viral, steroids and hormones, uterine stimulant, anticancer and other. Its clients range from small biopharmaceutical startups to some pharmaceutical companies. It has a manufacturing facility spread over 30,000 square feet (sq. ft.) area with a large batch-sized capacity for general: tablets, capsules, oral liquids, eye drops, ointments, lotions, creams, and others.
Valuation and market data
| Last close | ₹1503.00 |
|---|---|
| Market capitalisation | ₹985 crore |
| Enterprise value | ₹1,074 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.91 |
| Price to sales (TTM) | 2.96 |
| Book value per share | ₹517.16 |
| Dividend yield | 6.65% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹247 crore | ₹22 crore | ₹16 crore | 0.00 |
| Mar 2025 | ₹319 crore | ₹36 crore | ₹26 crore | 40.36 |
| Mar 2024 | ₹266 crore | ₹31 crore | ₹23 crore | 38.81 |
| Mar 2023 | ₹237 crore | ₹32 crore | ₹24 crore | 42.14 |
| Mar 2022 | ₹220 crore | ₹28 crore | ₹21 crore | 37.11 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 67.2% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 1.4% |
| Retail and others | 31.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.